⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NTLA News
Intellia Therapeutics, Inc
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
globenewswire.com
NTLA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intellia Therapeutics, Inc. - NTLA
accessnewswire.com
NTLA
Intellia Therapeutics Stock Alert: Intellia Investors with Financial Losses Encouraged to Contact Kehoe Law Firm, P.C. - NTLA
accessnewswire.com
NTLA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intellia Therapeutics, Inc. - NTLA
accessnewswire.com
NTLA
Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates
globenewswire.com
NTLA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intellia Therapeutics, Inc. - NTLA
accessnewswire.com
NTLA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intellia Therapeutics, Inc. - NTLA
accessnewswire.com
NTLA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intellia Therapeutics, Inc. - NTLA
accessnewswire.com
NTLA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intellia Therapeutics, Inc. - NTLA
accessnewswire.com
NTLA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intellia Therapeutics, Inc. - NTLA
accessnewswire.com
NTLA